Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests

被引:3
作者
Geiersbach, Katherine B. [1 ]
Bridge, Julia A. [2 ]
Dolan, Michelle [3 ]
Jennings, Lawrence J. [4 ]
Persons, Diane L. [5 ]
Souers, Rhona J. [6 ]
Tsuchiya, Karen D. [8 ]
Vasalos, Patricia H. [7 ]
Moncur, Joel T. [9 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Univ Minnesota, Med Sch, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol, Chicago, IL 60611 USA
[5] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA
[6] Coll Amer Pathologists, Dept Biostat, Northfield, IL USA
[7] Coll Amer Pathologists, Dept Proficiency Testing, Northfield, IL USA
[8] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA
[9] Walter Reed Natl Mil Med Ctr, Dept Pathol, 8901 Wisconsin Ave,Bldg 9,Basement,Room 0849, Bethesda, MD 20889 USA
关键词
HER-2/NEU GENE AMPLIFICATION; HER2; DUAL-COLOR; GUIDELINE RECOMMENDATIONS; CLINICAL ONCOLOGY/COLLEGE; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; FISH; TRASTUZUMAB; SOCIETY; CARCINOMA;
D O I
10.5858/arpa.2017-0457-CP
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Fluorescence in situ hybridization (FISH) and brightfield in situ hybridization (ISH) are 2 clinically approved laboratory methods for detecting ERBB2 (HER2) amplification in breast cancer. Objective.-To compare the performance of FISH and brightfield ISH on proficiency testing administered by the College of American Pathologists Laboratory Accreditation Program. Design.-Retrospective review was performed on 70 tissue core samples in 7 separate proficiency testing surveys conducted between 2009 and 2013. Results.-The samples included 13 consensus-amplified tissue cores, 53 consensus-nonamplified cores, and 4 cores that did not reach consensus for FISH and/or brightfield ISH. There were 2552 individual responses for FISH and 1871 individual responses for brightfield ISH. Consensus response rates were comparable for FISH (2474 of 2524; 98.0%) and brightfield ISH (2135 of 2189; 97.5%). The FISH analysis yielded an average HER2 copy number per cell that was significantly higher (by 2.86; P = .02) compared with brightfield ISH for amplified cores. For nonamplified cores, FISH yielded slightly, but not significantly, higher (by 0.17; P = .10) HER2 copy numbers per cell. There was no significant difference in the average HER2 to control ratio for either consensusamplified or consensus-nonamplified cores. Participants reported "unable to analyze" more frequently for brightfield ISH (244 of 2453; 9.9%) than they did for FISH (160 of 2684; 6.0%). Conclusions.-Our study indicates a high concordance rate in proficiency testing surveys, with some significant differences noted in the technical performance of these assays. In borderline cases, updated American Society of Clinical Oncology/College of American Pathologists cutoff thresholds that place greater emphasis on HER2 copy number per cell could accentuate those differences between FISH and brightfield ISH.
引用
收藏
页码:1254 / 1259
页数:6
相关论文
共 43 条
[11]   Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm [J].
Hanna, WM ;
Kwok, K .
MODERN PATHOLOGY, 2006, 19 (04) :481-487
[12]   RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing Experience From a National Reference Laboratory [J].
Hui, Ling ;
Geiersbach, Katherine B. ;
Downs-Kelly, Erinn ;
Gulbahce, Evin .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2017, 141 (02) :274-278
[13]   Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].
Joensuu, H ;
Kellokumpu-Lehtinen, P ;
Bono, P ;
Alanko, T ;
Kataja, V ;
Asola, R ;
Utriainen, T ;
Kokko, R ;
Hemminki, A ;
Tarkkanen, M ;
Turpeenniemi-Hujanen, T ;
Jyrkkiö, S ;
Flander, M ;
Helle, L ;
Ingalsuo, S ;
Johansson, K ;
Jääskeläinen, A ;
Pajunen, M ;
Rauhala, M ;
Kaleva-Kerola, J ;
Salminen, T ;
Leinonen, M ;
Elomaa, I ;
Isola, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820
[14]   ERBB2 AMPLIFICATION IN BREAST-CANCER ANALYZED BY FLUORESCENCE INSITU HYBRIDIZATION [J].
KALLIONIEMI, OP ;
KALLIONIEMI, A ;
KURISU, W ;
THOR, A ;
CHEN, LC ;
SMITH, HS ;
WALDMAN, FM ;
PINKEL, D ;
GRAY, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5321-5325
[15]   HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer [J].
Konecny, GE ;
Thomssen, C ;
Lück, HJ ;
Untch, M ;
Wang, HJ ;
Kuhn, W ;
Eidtmann, H ;
du Bois, A ;
Olbricht, S ;
Steinfeld, D ;
Möbus, V ;
von Minckwitz, G ;
Dandekar, S ;
Ramos, L ;
Pauletti, G ;
Pegram, MD ;
Jänicke, F ;
Slamon, DJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1141-1151
[16]   Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer [J].
Lim, Tse Hui ;
Lim, Alvin Soon Tiong ;
Thike, Aye Aye ;
Tien, Sim Leng ;
Tan, Puay Hoon .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (02) :140-147
[17]   The New Equivocal Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines [J].
Long, Thomas H. ;
Lawce, Helen ;
Durum, Connie ;
Moore, Stephen R. ;
Olson, Susan B. ;
Gatter, Ken ;
Troxell, Megan L. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (02) :253-262
[18]   Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer [J].
Mansfield, Aaron S. ;
Sukov, William R. ;
Eckel-Passow, Jeanette E. ;
Sakai, Yuta ;
Walsh, Frank J. ;
Lonzo, Melissa ;
Wiktor, Anne E. ;
Dogan, Ahmet ;
Jenkins, Robert B. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 139 (02) :144-150
[19]   Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization [J].
Mayr, Doris ;
Heim, Sibylle ;
Weyrauch, Kerstin ;
Zeindl-Eberhart, Evelyn ;
Kunz, Anne ;
Engel, Jutta ;
Kirchner, Thomas .
HISTOPATHOLOGY, 2009, 55 (06) :716-723
[20]   IDENTIFICATION OF AMPLIFIED DNA-SEQUENCES IN BREAST-CANCER AND THEIR ORGANIZATION WITHIN HOMOGENEOUSLY STAINING REGIONS [J].
MULERIS, M ;
ALMEIDA, A ;
GERBAULTSEUREAU, M ;
MALFOY, B ;
DUTRILLAUX, B .
GENES CHROMOSOMES & CANCER, 1995, 14 (03) :155-163